Datadog Inc vs Nuwellis Inc — how do they compare? Datadog Inc trades at $272.51 (market cap $97.43B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Datadog Inc is far larger — about 44286.4× Nuwellis Inc's market cap, and Datadog Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and Nuwellis Inc for 26 Days on average.
| DDOG | NUWE | |
|---|---|---|
Market Cap | $97.43B | $2.20M |
Volume | 1,586,926 | 121,544 |
Sector | Technology | Health |
52-Week High | $288.15 | $146.65 |
52-Week Low | $102.62 | $0.68 |
Typical Hold Time | 76 Days | 26 Days |
Enterprise Value | $93.72B | -$1.52M |
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $271.34, down 2.48% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while oscillators are neutral. Fundamentally, revenue growth is robust, rising from $1.7B in 2022 to $3.43B in 2025, though net income margins are volatile. Recent earnings beats and accelerating enterprise customer adoption, particularly in AI and cloud observability, support positive sentiment.
The outlook is favorable given analyst consensus and AI-driven demand, but high valuation multiples (P/E 542.68) and negative net cash flow pose risks. Upside potential exists if the company sustains earnings momentum and expands profitability. Key risks include competitive pressures and execution challenges in a high-growth environment.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →